Guggenheim raised the firm’s price target on Savara (SVRA) to $11 from $8 and keeps a Buy rating on the shares following what the firm calls “a series of positive updates from the company” over the past several weeks. Following these updates, the firm now estimates peak probability-adjusted annual U.S. Molbreevi sales of $962M, up from a prior view of $680M, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SVRA:
- Savara price target raised to $8 from $6 at Oppenheimer
- Savara price target raised to $8 from $5 at H.C. Wainwright
- Savara’s Expanding aPAP Market and Strategic Moves Justify Buy Rating with Increased Price Target
- Savara Highlights MOLBREEVI Development in New Presentation
- 3 Best Stocks to Buy Now, 8/22/2025, According to Top Analysts